The GLP-1 Decade
Kevin Beardsley@kbeards
+3.3%
since Oct 1
The idea
I believe GLP-1 drugs become a lasting fixture of American life over the next decade, not just a passing hit, and I want exposure across the whole chain that benefits. So this holds the drugmakers themselves alongside the pens, sterile filling and lab equipment every new drug needs, the distributors getting them to patients, and the protein brands and fresh grocers that gain as eating habits shift. No single name dominates, and I keep a small cash reserve rather than concentrating on one bet. I'd rethink this if the drugs plateau or if patients stop staying on them long term.
What it owns
- Smaller appetites paired with higher protein intake and fresh food preferences reshape grocery and restaurant spending away from traditional snacks. · BellRing BrandsPremier Protein shakes directly address the medical guidance that GLP-1 users eat less but protect muscle by consuming more protein., Chipotle Mexican GrillThe restaurant format fits a GLP-1 diet perfectly: customers pick protein, skip what they do not want, and smaller portions still satisfy., Sprouts Farmers MarketBuilt around fresh produce and protein, the grocer wins as GLP-1 users shift away from packaged snacks toward whole foods., Simply Good FoodsQuest and Atkins brands are built for smaller, protein-heavy eating, which matches how people on these drugs naturally adjust their diet., Vital FarmsOwns the premium end of the egg market, the cheapest whole-food protein available and central to the fresh-and-protein shift., Tyson FoodsThe scale supplier of chicken, beef, and pork, so it wins if total protein demand rises as GLP-1 adoption spreads.32%
- These companies make the GLP-1 drugs themselves and drive the category forward through innovation and market share. · Eli LillyZepbound and Mounjaro anchor the category as the largest sellers, and the take needs their obesity drug sales to keep growing as GLP-1s become routine., Novo NordiskNovo Nordisk created the modern GLP-1 market with Ozempic and Wegovy and retains a dominant share of prescriptions, making it a core holding in a take built on GLP-1 expansion., AmgenAmgen's MariTide offers a monthly dosing option instead of weekly shots, representing the kind of next-wave innovation needed as GLP-1s grow from niche products into standard care., Viking TherapeuticsA small, pure bet that the GLP-1 market grows large enough for new entrants to succeed through strong trial data and market entry.26%
- Injector pens, manufacturing equipment, and sterile filling capacity get built and replaced regardless of which drugmaker leads, creating steady demand across the supply chain. · West Pharmaceutical ServicesManufactures the stoppers, plungers, and delivery parts inside every GLP-1 pen, so it gets paid on total injectable volume regardless of which drug wins., DanaherSupplies the equipment and consumables that drugmakers use to manufacture obesity drugs at scale, winning as the industry expands capacity., Thermo Fisher ScientificProvides lab equipment and contract manufacturing services for new obesity drugs, including scarce sterile filling capacity that remains in short supply., Stevanato GroupManufactures the pens and glass containers that hold GLP-1 drugs, so it wins on total category volume independent of brand.22%
- Distributors and telehealth platforms collect fees on every prescription as GLP-1 volumes climb for years. · McKessonMoves a huge share of US prescriptions and collects a distribution fee on every GLP-1 box flowing through its network., CencoraThe other major distributor moving these drugs to pharmacies with the cold-chain handling they require, paid on volume regardless of brand., Hims & Hers HealthThe direct-to-consumer telehealth channel for GLP-1 access without a specialist, and weight loss is now its fastest-growing business line.12%
- Cash8%